Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABHD14A
REST API REST API
Homo sapiens
ABHD14A is differentially expressed in 296 experiments: 114 organism parts: cerebellum, placenta, ... (112 more);, 143 disease states: normal, glioblastoma, ... (141 more);, 72 cell types 311 cell lines 186 compound treatments and 60 other conditions.
Synonyms DORZ1, DKFZP564O243
Orthologs Abhd14a (Mus musculus)   ABHD14A (Danio rerio)   ABHEA_RAT (Rattus norvegicus)   ENSXETG00000031804 (Xenopus tropicalis)   ENSXETG00000001631 (Xenopus tropicalis)   ENSCING00000021807 (Ciona intestinalis)   (Compare orthologs)
Gene Ontology Term cytoplasm, membrane, integral to membrane, hydrolase activity
UniProt Accession C9IYJ8, C9J7W8, C9JFX6, C9JMW6, Q9BUJ0, A6NCZ0, F5H1J2
InterPro Term Alpha/beta hydrolase, N-terminal
Search EB-eye ENSG00000248487
Show more properties
Experimental Factors
organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-30573, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-19639, E-GEOD-18005, E-GEOD-2549, ... (36 experiments)

Factor Value U/D Experiments
HL-60
3
E-MTAB-37, E-GEOD-5258, E-GEOD-24147
HeLa
3
E-GEOD-20081, E-MTAB-62, E-GEOD-4483
Caco-2
2
E-GEOD-1474, E-GEOD-1862
DU4475
2
E-MTAB-37, E-GEOD-10890
EFM19
2
E-MTAB-37, E-GEOD-10890
MT3
2
E-MTAB-37, E-GEOD-10890
305 more value(s).


cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-66, ... (43 experiments)

Factor Value U/D Experiments
mononuclear
2
E-GEOD-9196, E-GEOD-13987
plasma cell
2
E-MEXP-2360, E-GEOD-6691
fibroblast
1
2
E-GEOD-23402, E-GEOD-13548, E-GEOD-3920
mesenchymal stem cell
1
E-GEOD-9894
CD34+CD38-/lowCD19+ cell
1
E-MEXP-1403
naive T cell
1
E-GEOD-1460
66 more value(s).


disease state

studied in E-GEOD-3307, E-GEOD-16134, E-GEOD-2466, E-GEOD-16515, E-GEOD-14924, ... (49 experiments)

Factor Value U/D Experiments
normal
6
14
E-TABM-282, E-GEOD-18842, E-GEOD-16134, E-GEOD-2719, E-GEOD-9692, ... (20 experiments)
anaplastic large cell lymphoma
2
E-MTAB-62, E-GEOD-6338
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
myeloma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
acute myeloid leukemia
1
2
E-GEOD-14924, E-MTAB-37, E-MTAB-62
137 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-23031, E-GEOD-7400, E-MTAB-798, E-GEOD-3720, ... (32 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5741, E-MEXP-2590, E-TABM-868, E-GEOD-5824, E-GEOD-5099, ... (12 experiments)
5-aza-2'-deoxycytidine
1
1
E-MEXP-1269
ketoconazole 0.6 micromolar
1
E-MTAB-798
perhexiline 15 micromolar
1
E-MTAB-798
allopurinol 28 micromolar
1
E-MTAB-798
gemfibrozil 20 micromolar
1
E-MTAB-798
180 more value(s).


RNAi

studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Factor Value U/D Experiments
Dharmacon control
1
E-MEXP-1857
siRNA-mediated CDC7 inhibition
1
E-MEXP-2115
Luc siRNA
1
E-GEOD-3697
HDAC8 knockdown
1
E-GEOD-12438
HSF1 siRNA #2
1
E-GEOD-3697
shRNA mSin3a-b
1
E-MEXP-1509
3 more value(s).


alive at endpoint
studied in E-GEOD-4922

biosource provider
studied in E-GEOD-19466

Blood/non-blood meta-groups
studied in E-MTAB-62

cancer site
studied in E-GEOD-4271

cellular component
studied in E-GEOD-1400

chromosomal aberration
studied in E-GEOD-1729

clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-7696, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, ... (15 experiments)

clinical treatment
studied in E-GEOD-6532

developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-22601, E-MTAB-62

disease staging
studied in E-GEOD-19804, E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (7 experiments)

environmental stress
studied in E-GEOD-3720

estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922

genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-GEOD-6431, ... (6 experiments)

genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-MEXP-421, E-GEOD-18005, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-GEOD-20540, E-MEXP-1446, ... (10 experiments)

histology
studied in E-TABM-234, E-GEOD-12452, E-GEOD-21653

immunoprecipitated protein
studied in E-GEOD-21918

individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-555

injury
studied in E-GEOD-19743

irradiate
studied in E-GEOD-2742

karyotype
studied in E-GEOD-22056

ki67 ihc
studied in E-GEOD-21653

light
studied in E-GEOD-1725

material type
studied in E-MEXP-455

media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

metastasis
studied in E-GEOD-18105

molecular subtype
studied in E-GEOD-21653

organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426

organism status
studied in E-GEOD-19188

performer
studied in E-GEOD-2004

phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-5824, E-GEOD-17636, ... (7 experiments)

population
studied in E-GEOD-4922

progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

protocol type
studied in E-GEOD-3254, E-GEOD-19249, E-GEOD-19246, E-GEOD-1343

read length
studied in E-GEOD-30222

replicate
studied in E-GEOD-10797, E-GEOD-10896

sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

sampling time point
studied in E-GEOD-16797, E-MTAB-798, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

sex
studied in E-GEOD-2466, E-GEOD-7307

sirna
studied in E-GEOD-21575

stimulus
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984

strain or line
studied in E-MEXP-1996, E-TABM-125

subtype
studied in E-GEOD-24283

survival time
studied in E-GEOD-3494, E-GEOD-19188

test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

transfection
studied in E-GEOD-14680

treatment
studied in E-GEOD-34055, E-GEOD-32685, E-MEXP-973, E-GEOD-34635, E-GEOD-19246, ... (8 experiments)

tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

weight of protein recovered
studied in E-GEOD-21918

Processing time: 1.513 secs.
 
Gene Expression Atlas 2.0.13- 4/23/12 11:55:46 AM